TWI241346B - Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same - Google Patents
Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same Download PDFInfo
- Publication number
- TWI241346B TWI241346B TW92134947A TW92134947A TWI241346B TW I241346 B TWI241346 B TW I241346B TW 92134947 A TW92134947 A TW 92134947A TW 92134947 A TW92134947 A TW 92134947A TW I241346 B TWI241346 B TW I241346B
- Authority
- TW
- Taiwan
- Prior art keywords
- vaccine
- virus
- lpc
- tissue culture
- strain
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 130
- 241000700605 Viruses Species 0.000 title claims abstract description 119
- 238000012136 culture method Methods 0.000 title claims abstract description 8
- 206010008631 Cholera Diseases 0.000 title abstract description 6
- 241000282898 Sus scrofa Species 0.000 claims description 72
- 206010037660 Pyrexia Diseases 0.000 claims description 37
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 33
- 239000002953 phosphate buffered saline Substances 0.000 claims description 31
- 239000003223 protective agent Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000002480 mineral oil Substances 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- -1 (vinyl) hexyl Chemical group 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 241000710777 Classical swine fever virus Species 0.000 abstract description 16
- 230000001681 protective effect Effects 0.000 abstract description 4
- 241000282887 Suidae Species 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 39
- 230000003053 immunization Effects 0.000 description 26
- 238000002649 immunization Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 206010058874 Viraemia Diseases 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000006651 lactation Effects 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000002480 immunoprotective effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010004053 Bacterial toxaemia Diseases 0.000 description 3
- 208000001726 Classical Swine Fever Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000202347 Porcine circovirus Species 0.000 description 3
- 208000013222 Toxemia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
- 235000005809 Carpobrotus aequilaterus Nutrition 0.000 description 1
- 244000187801 Carpobrotus edulis Species 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 235000004550 Disphyma australe Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940105596 baytril Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000021596 pentasomy X Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1241346 玖、發明說明: 【發明所屬之技術領域】 、本案係關於-種豬雜織培養活毒疫苗病毒株,以及其組織培養方 法。本發日紳_含有該兔化豬麵毒株之_ 麵 ^, 其顯示對抗豬遮之良好保護效果。 【先前技術】 —豬瘦(hog cholera ; classical swine fever)是由據過性病毒所引起之 —種高度觸性敗血症,以全雜出血及魏粒要徵兆。豬疲最早 於1810年發生於美國田納西州,但首次確診為諸瘦病例則屬^年 發生於美國愛荷M者’ #時造成養贿極大_失。丨年傳至歐 洲’然後散佈至世界其他各地。在臺灣,魅自日據喊即發生且頗 為福獗’目前仍為台灣最重要之豬隻傳染病之―,且依動物傳染病防 治條例被列為甲類動物傳染病。 豬瘟病毒是屬於黃絲科(Flavi祕ae)、跡鱗屬(pestivims) 之RNA病毒’分子量約4 χ 6道耳吞’其核酸具有感染力。豬疲病毒 在ΡΗ Μ之間最為穩定,尤於微驗性更穩定。於ρΗ 3時,病毒會被破 壞。另因具妹膜’含有脂質成分,故對⑽、氣仿或去氧膽^敏 感,對於Tween 80等清潔劑、蛋自酶魏蛋自轉料也很敏感。 豬-互感染後以持續性高溫⑷i饥)及全雜心為主要 徵’感神與死亡料雜9觀國。—錄Μ急軸程,但可 轉為慢性。在甚急性病例僅見極輕微的病變,甚或沒有病變即死亡, 而在急性和亞急性病例則可見相當嚴重的病變,如血管内皮細胞呈水 腫變性和壞死,錢機制受到破壞,產生身齡織和龜,特 ^於淋巴結及賴的廣泛性描和丨血(行政院農業委貝會動植物二 1241346 古坏f η病母之病I毒力差異頗大,強毒株可引發急性病例而導致 _ : ^剌起亞紐與慢性絲,弱毒制可能造成不顯 但弱毒株可能會引起胎兒與魅仔豬之死亡。由於豬疲病毒 僅存清型’故採用免疫血清學方法,如免疫擴散法或營光標 不抗體木色鱗’皆無法區繼餅外毒與兔化職疫苗毒,雖國外 有學者發細料株的單源抗體進行競爭結合法及抗原捕捉法以區分 豬遮野外毒及統豬賴縣,但方法較為複雜。 在1952年紐森博士及李崇道博士由菲律賓引進r〇vac株兔化豬 痕病毒’後續經林再春博士以家兔繼代雛而獲得Lpc_chi⑽立製成 疫苗後廣泛使用’ _使台灣之豬餅到良好控制。然而,由^兔化 豬瘂疫苗雜取接種家兔之賴聽巴結為之製造材料,製備疫苗之 過程中操作較麻煩。又,綴接種之家兔種品綠亂且傭差異大, 因而造成製造的疫苗之品管;^。因此’確有必要研發具有保護豬隻 之良好效果且無上述缺點之豬瘟疫苗。 【發明内容】 為解決先前技術之豬瘟疫苗存在之問題,本案之發明人已針對 LPC-China株病毒於組織細胞内之性狀詳加研究,且嘗試利用組織培養 方法來開發組織培養疫苗。經比較LPC-China株病毒在豬腎、豬睪丸 初代細胞及多種豬源株化細胞中之增殖性狀後,已發現Lpc_china猪 病毒在PK-CL豬源株化細胞中之增殖最佳,因而成功研發出組織培養 細胞馴化之LPC-TS株病毒。此外,利用未被第一型豬環狀病毒(pcv 污染的PK-15-KL細胞中增殖之LPC-TS株病毒與乳糖及聚乙稀基叶匕 咯啶酮(PVP)混合所製得之冷凍乾燥疫苗亦顯示出對豬隻有完全之免 疫保護效力。 本發明係提供一種新穎之兔化豬瘟毒組織培養疫苗病毒株,即 LPC-TS株病毒,其特徵在於其係經LPC-China株兔化豬瘦瘦苗第812 6 1241346 批豬瘦病毒株於PK-15株化細胞中繼代培養至第十七代,期間利用 END及螢光標示抗體染色技術,以極限稀釋法予以株選各一次,在繼 代培養第十八代後於未被第一型豬環狀病毒污染之細胞中 增殖而得。 經反轉錄聚合酶鏈反應技術及核酸序列分析比對後,已發現本發明 之LPC-TS株病毒在其3,端非轉譯區核酸上有12至15個胸腺核苷 (poly-X)之插入’其未見於其他習知之兔化豬痕疫苗病毒株中。亦即, 與LPC兔化豬疲疫苗大陸株hclv (accession number : AF0915〇7)相 車父’本發明之LPC-TS株病毒之相對應核酸序列1214〇 bp位置上有一 段12至15個T之插入,可作為確認LPC_TS疫苗病毒株之基因標記用。 再者,LPC-TS株病毒對保有低移行抗體之小豬具有良好的保護效力, 但在南移行抗體(1:32〜1:214)之下則必須有i〇4G TCID5〇之病毒含量始 能克服移行抗體之干擾。 本發明中使用之PK-15株化細胞係由美國農業部國家動物疾病中 心(NADC)之Dr· Kelly M· Lager所分讓,經行政院農委會家畜衛生試驗 所證貫,此株化細胞未被第一型豬環狀病毒(pcvi)及黴漿菌 (myC〇plasma)污染,故另將此PK-15細胞命名為pK-15-kl細胞,以與 其他PK-15細胞區別。 本發明為有關於一種製備兔化豬瘟毒組織培養疫苗病毒株之組織 培養方法,其係包括使LPC-China兔化緒瘟疫苗病毒株於被第一型豬 環狀病毒污染之PK-15株化細胞中增殖繼代,於第十八代後病毒係於 無第型豬環狀病毒污染之PK-15-KL株化細胞中增殖而製得lpc_ts 株病毒。在本發明之方法巾,所使狀LPC_China統_疫苗病毒 株係以家兔繼代812次。 相較於以往兔化豬瘟疫苗須採取接種家兔之脾臟及淋巴結作為製 造疫苗之材料,本發明之製備LPC_TS組織培養疫苗病毒株之方法係採 組織培養方式,可使病毒增殖較為方便且操作較為簡單,直較容易控 1241346 制疫苗之品質。 本發明也”含有餘組織培養活毒疫苗病毒彳朱d盘組織 培養活毒疫苗,其特徵在於其包含於未被第一型豬環狀病毒污染之 PK-l^KL細胞中增殖製得之LPC-TS豬瘟病毒株。 本舍明之豬瘦組織培養活毒疫苗,其可呈冷康乾燥形式,且其可額 外包含保護劑。較佳之保護劑包括乳糖及聚乙烯基吡咯啶酮(pvp)。根 據本發明,所使用之保護劑係由乳糖及聚乙烯基吡咯啶酮組成。較佳 地’保護劑由相對於疫苗總體積之約5至約12%重量/體積之乳糖及約 〇.2至約0.5%重量/體積之聚乙烯基吡咯啶酮組成。更佳地,保護劑由 相對於疫苗總體積之約10%重量/體積之乳糖及約〇·3%重量/體積之聚 乙烯基吡嘻咬酮組成。 本發明之冷✓東乾燥豬疲活毒疫苗係於動物免疫接種前與稀釋液混 a。用於此目的之稀釋液可為一般熟諳此藝者所知者。較佳地,本發 明使用之稀釋液為磷酸鹽緩衝液(PBS)、礦物油劑(〇E)、純水或5%葡 萄糖。更佳地,稀釋液為磷酸鹽緩衝液、礦物油劑或純水。最佳地, 本’X明使用之稀釋劑為碟酸鹽緩衝液。在本發明中,含有約2毫升 LPC-TS病毒液及保護劑混合液之冷凍乾燥豬瘟組織培養活毒疫苗(約 20劑畺/瓶)中可加入約40毫升之稀釋液,以用於動物疫苗接種。 又,本案之發明人已針對多株之豬瘟野外毒與豬瘟疫苗毒之病毒核 酸差異性,成功設計出針對兔化豬瘟疫苗毒特異性之引子,故以該引 子對檢測樣品進行反轉錄聚合酶鏈反應(RT-PCR)時,若該樣品中存在 兔化豬瘟疫苗毒,必定出現特異性2RT_pCR產物,而野外豬瘟毒則無 此產物出現’因此’本發明之特異性引子可有效用於區別豬瘟野外毒 與豬瘟疫苗毒。 本發明混合後之緒瘟活毒疫苗可使用肌肉或皮下注射方式接種豬 隻。接種部位可為耳後頸部、背部、臀部肌肉或皮下。較佳,接種係 藉由耳後頸部肌肉或皮下注射進行。一般而言,本發明之藉:盘活毒疫 1241346 :用方、仔豬之免疫接種方式魏下列兩種方式巾視情況選擇其中—種 =施預防注射··-、種母豬完成基礎免疫後,約於配種前免疫注射一 久’以後不再免疫注射者,其所生仔豬分別於第三週齡及第六週齡時 主射第-劑及第—劑豬癌疫苗;以及二、種母豬完成基礎免疫後,每 年於工胎時免疫注射者,其所生仔豬約於第六週齡及第九週齡時分 別庄射第及第_劑豬痕疫苗。此外,本發明之兔化豬瘦疫苗用於 母豬之〜免疫接種方式射就下列_方式視情況 防注射:—、第-次配猶免纽射—缝,以後不再免疫注射;3 及二、每年一次空胎時注射一劑量。 【實施方式】 下列實例係用以說明本發明之技術内容及可達成之功效但 非用以限制本發明。凡依本發明所作之任何均等變化及修飾,皆 屬本發明申請專利範圍之範轉。 豬瘦组織培養活毒疫苗病毒株及疫苗之製備1241346 (ii) Description of the invention: [Technical field to which the invention belongs] This case is about a breeding pig weaving culture live virus vaccine strain and its tissue culture method. The present Japanese gentleman _ face ^ containing the rabbitized pig face strain, which shows a good protective effect against pig cover. [Prior technology]-Hog cholera (classic swine fever) is caused by a virus.-A type of highly contagious septicemia, with signs of total miscellaneous bleeding and Wei granules. Pig fatigue first occurred in Tennessee in the United States in 1810, but the first diagnosed cases of lean cases were in ^ years. Occurred in the United States in Iowa ’’s, causing bribery.丨 spread to Europe ’and spread to other parts of the world. In Taiwan, Meiji has been called out and is a blessing. It is still one of the most important pig infectious diseases in Taiwan, and it is classified as a Class A animal infectious disease under the Animal Infectious Diseases Control Ordinance. Classical swine fever virus belongs to the family of Flaviaceae and pestivims. It is an RNA virus with a molecular weight of about 4 x 6 channels and its nucleic acid is infectious. Porcine fatigue virus is the most stable among PGs, and is more stable in particular. At ρΗ 3, the virus will be destroyed. In addition, because it has a lipid component, it is sensitive to radon, aerobic or deoxycholin, and it is also sensitive to detergents such as Tween 80, egg autoenzyme and egg autotransformer. The main symptoms of pig-mutual infection are persistent high temperature and hunger), and full-heartedness. Feelings and death are mixed. -Record M acute axis course, but can be changed to chronic. In very acute cases, only very slight lesions are seen, or even death without lesions, while in severe and subacute cases, quite severe lesions can be seen, such as edema degeneration and necrosis of vascular endothelial cells, damage to the money mechanism, and age and organization. Extensive descriptions of turtles, special lymph nodes, and blood (blood of the Executive Yuan Agricultural Committee, Animal and Plant II 1241346, ancient bad f η disease mother disease I have quite different virulence, and virulent strains can cause acute cases and cause _ : ^ Kianov and chronic silk, the weak virus system may cause insignificant but the weak strain may cause the death of the fetus and the charm piglet. Because the pig fatigue virus only has the clear type ', immunoserological methods such as immunodiffusion method or camp The cursor does not have antibodies against wood-colored scales, which can't distinguish between the pancake external virus and the rabbit chemical vaccine. Although some foreign scholars have sent single-source antibodies of fine strains to compete with the binding method and antigen capture method to distinguish the pig wild virus and the system. Zhulai County, but the method is more complicated. In 1952, Dr. Newson and Dr. Li Chongdao introduced the rovavac strain of rabbitized swine scar virus from the Philippines. Later Dr. Lin Zaichun obtained Lpc_chi from rabbits. It has been widely used after making vaccines. _Taiwanese pig cakes are well controlled. However, the rabbit rabbit pig vaccine is used to mix the materials used to inoculate rabbits, and the operation is more troublesome in the process of preparing vaccines. In addition, the breeds of rabbits inoculated with vaccinated rabbits are very messy and the commission varies greatly, which leads to the quality control of the manufactured vaccines; therefore, 'it is indeed necessary to develop a swine fever vaccine that has good effects in protecting pigs and does not have the above-mentioned disadvantages. [Summary of the Invention] In order to solve the problems existing in the swine fever vaccine of the prior art, the inventors of this case have conducted detailed studies on the traits of the LPC-China strain virus in tissue cells, and have tried to develop tissue culture vaccines using tissue culture methods. After comparing the proliferative traits of LPC-China strain virus in porcine kidney, pig testis primary cells, and various strains of pig-derived strains, it has been found that Lpc_china pig virus has the best proliferation in PK-CL pig-derived strains, so it was successfully developed LPC-TS strain virus domesticated from tissue culture cells. In addition, the LPC-TS strain virus and lactose and polyethylene, which were not propagated in PK-15-KL cells contaminated with type 1 porcine circular virus (pcv), were used. The freeze-dried vaccine prepared by the mixture of leaf drolidone (PVP) also showed complete immunoprotective effect on pigs. The present invention provides a novel rabbitized swine fever tissue culture vaccine virus strain, namely LPC-TS Strain of virus, characterized in that it is a rabbit strain of lean pig strain LPC-China strain 812 6 1241346. The batch of pig lean virus strains were subcultured to the seventeenth generation in PK-15 strain cells. The light-labeled antibody staining technique was used to select each strain by the limiting dilution method, and it was obtained after the eighteenth generation of subculture and was proliferated in cells not contaminated by type 1 porcine circular virus. After reverse transcription polymerase chain reaction After the technology and nucleic acid sequence analysis and comparison, it has been found that the LPC-TS strain virus of the present invention has 12 to 15 thymidine (poly-X) insertions on its 3, untranslated region nucleic acid, which is not seen in other studies. Known in rabbit strain of swine scar vaccine virus. That is to say, with the LPC rabbitized pig fatigue vaccine continental strain hclv (accession number: AF0915〇7), the car parent 'corresponding nucleic acid sequence of the LPC-TS strain virus of the present invention has a segment of 1214 bp at 12 to 15 T The insertion can be used to confirm the genetic marker of the LPC_TS vaccine virus strain. In addition, the LPC-TS strain virus has a good protective effect on piglets with low migration antibodies, but the virus content of i04G TCID50 must be under the southern migration antibody (1: 32 ~ 1: 214). Can overcome the interference of migration antibodies. The PK-15 strain cell line used in the present invention was assigned by Dr. Kelly M. Lager of the National Animal Disease Center (NADC) of the U.S. Department of Agriculture. The cells were not contaminated with Porcine Circovirus I (pcvi) and mycoplasma, so this PK-15 cell was also named pK-15-kl cell to distinguish it from other PK-15 cells. The invention relates to a tissue culture method for preparing a rabbitized swine fever virus tissue culture vaccine virus strain, which comprises administering the LPC-China rabbit strain of Xuzheng vaccine virus strain to PK-15 contaminated by type 1 swine circular virus. Subcultured cells proliferated in subsequent generations. After the eighteenth generation, the virus was propagated in PK-15-KL strain-free cells contaminated with type 1 porcine circular virus, and the lpc_ts strain virus was obtained. In the method of the present invention, the LPC_China system_vaccine virus strain was subcultured to rabbits 812 times. Compared with the previous rabbit swine fever vaccine, the spleen and lymph nodes of rabbits must be inoculated as a vaccine manufacturing material. The method for preparing the LPC_TS tissue culture vaccine virus strain of the present invention adopts a tissue culture method, which can make the virus proliferation more convenient and easy to operate. It is simpler and easier to control the quality of 1241346 vaccine. The present invention also contains a live tissue culture live virus vaccine virus spleen dwarf disk culture tissue live vaccine, which is characterized in that it is produced by proliferation in PK-1KL cells that are not contaminated by type 1 porcine circular virus. LPC-TS Classical Swine Fever Virus Strain. Bensmin's pig lean tissue culture live virus vaccine can be in the form of Lengkang dry, and it can additionally contain a protective agent. Preferred protective agents include lactose and polyvinylpyrrolidone (pvp ). According to the present invention, the protective agent used is composed of lactose and polyvinylpyrrolidone. Preferably, the protective agent is from about 5 to about 12% weight / volume of lactose and about 0 to the total volume of the vaccine. .2 to about 0.5% weight / volume of polyvinylpyrrolidone. More preferably, the protective agent consists of about 10% weight / volume of lactose and about 0.3% weight / volume of polymer relative to the total volume of the vaccine. It is composed of vinylpyrrolidone. The cold ✓ East dry porcine toxin vaccine is mixed with diluent a before immunization of animals. The diluent used for this purpose can be known to those skilled in the art. Preferably, the diluent used in the present invention is a phosphate buffer solution (P BS), mineral oil (0E), pure water or 5% glucose. More preferably, the diluent is phosphate buffered saline, mineral oil or pure water. Most preferably, the diluent used in this invention is Dish salt buffer solution. In the present invention, about 40 ml of the freeze-dried swine fever tissue culture live virus vaccine containing about 2 ml of a mixture of LPC-TS virus liquid and a protective agent can be added The diluted solution is used for vaccination of animals. In addition, the inventors of the present case have successfully designed primers specific for rabbit swine fever vaccine virus specificity for the differences between the virus nucleic acids of the swine fever field virus and the swine fever vaccine virus. Therefore, when using this primer to perform reverse transcription polymerase chain reaction (RT-PCR) on a test sample, if a rabbit swine fever vaccine virus is present in the sample, a specific 2RT_pCR product must be present, but there is no such product in the wild swine fever virus It appears that “specific” primers of the present invention can be effectively used to distinguish wild swine fever virus from classical swine fever vaccine. The mixed fresh fever virus vaccine of the present invention can be used to inoculate pigs by muscle or subcutaneous injection. The inoculation site can be Back ear, neck, back, buttock muscles Or subcutaneously. Preferably, the inoculation is performed by intramuscular or subcutaneous injection behind the ear and neck. Generally speaking, the present invention borrows: Toxicosis 1241346: the use of prescription, piglet immunization methods, the following two methods, depending on the situation Choose among them-seed = preventive injection ··-, after the sow has completed the basic immunization, and the immunization is about a long time before breeding, and the person who is no longer immunized will be born at the third week and the sixth week. The first shot and the first dose of pig cancer vaccine were shot at the time; and the second and sow pigs were vaccinated every year at the time of working babies after completing the basic immunization, and the piglets born were around the sixth and ninth weeks of age. The Zhuang shot and the first dose of pig scar vaccine are separately. In addition, the rabbitized pig lean vaccine of the present invention is used for sows. The immunization method is as follows: Shoot-sewing, no more immunizations will be given in the future; 3 and 2, once a year, a single dose will be injected when the fetus is empty. [Embodiment] The following examples are used to explain the technical content and achievable effects of the present invention but not to limit the present invention. Any equal changes and modifications made in accordance with the present invention are all within the scope of the patent application scope of the present invention. Swine lean tissue culture live virus vaccine virus strain and vaccine preparation
LPC-TS豬疲組織.接卷疫苗種卷 首先以Eagle’s MEM (EMEM)細胞維持液(含2%牛胎兒血清)溶網 自行政院農業委員會家畜衛生試驗所之第812批Lpc china兔化豬癌 疫苗’取病毒液接種於PK-15株化細胞中,在听暖箱中吸著9〇至 ⑽分鐘,然後以EMEM培她青洗PK七細胞三次再加人emeiv 細胞維持液,將其置於37°C暖箱巾培養三至四天,並將經齡之㈣ 細胞置於-8(TC冰櫃中冷床之。此培_程於第一代至第+七代之御 培養方法巾皆為相同’但第权代之後改_無第—型株環狀病毒g 染之PK-15-KL株化細胞來增殖病毒而得到[pc 丁§广主 1241346 LPC-China病毒第一代至第十七代之繼代培養過程期間,利用END (Exaltation of Newcastle Disease)及螢光標示抗體染色技術,且以極限稀 釋法予以株選(cloning),其中係將LPC-TS病毒以EMEM細胞維持液 進行10倍稀釋,再將10倍稀釋液分別接種於24孔培養盤内之PK-15 細胞中,經3至4天後先收集病毒液,再以螢光標示抗體染色技術測 定在何孔中細胞有螢光之出現,取接種最高稀釋病毒液且出現螢光之 病毒液作為種毒,以製造LPC-TS病毒。 細胞之培養 在36.5-37 C溫度下將PK-15-KL株化細胞在培養瓶内於細胞生長培 養液(每1000毫升含有50-80毫升牛胎兒血清、〇·7公克NaHC03及 Eagle’s MEM)中培養72至96小時,然後將培養瓶内之細胞培養液倒 棄,並加入適量PBS溶液清洗細胞層並將PBS倒棄。接著,加入適量 Trypsin Versene (TV)消化液後,將培養瓶置入3r>c暖箱内使細胞圓化, 搖晃或敲打該培養瓶以使細胞脫落。將細胞液倒入無菌離心管内且以 300 X g離心五分鐘。將上清液抽除後,加入少量生長培養液且以無菌 注射長針筒沖散,再以細胞培養液調配成為3〇〇,〇〇〇細胞/毫升之細胞 浮游液。 病毒株之增殖 將已形成60%-70%單層之上述pK_15_kl細胞培養液倒棄,將 LPC-TS 製造用種毒(working seed vims)以約 〇 丨 M〇I (multiplicato 〇f infection)的病毒量接種於細胞中,且將培養瓶置入37〇c恆溫室使細胞 吸著1.5小時,然後加入病毒增殖用培養液(每1〇〇〇毫升含有1〇_2〇毫 升牛胎兒血清、0·7公克NaHC〇3及Eagle,s MEM),繼續培養於37°c恆 溫室中3至4日後,將感染細胞予以凍結解凍一次,再經looo 離 〜去除細胞碎片。收集上清液,再以45〇舰之濾膜過濾,得到之濾液 即為疫苗製賴之絲原液,將該病毒原液置於.贼冰櫃保存備用。 LPC-TS病毒力價測$ 1241346 稀釋於細胞生長培養液(Eagle’s MEM,其中含5%牛胎兒血清 (Hyclone)、100 u/ml 盤尼西林、1〇〇 pg/ml 鏈黴素及 10 mM HEPES,且 以7.5%NaHC〇3調節pH)中之PK-15-KL細胞先培養於96孔盤中,隔 天待細胞單層達60-70%滿時,將細胞培養液甩棄,然後將10倍稀釋之 病毒液以每孔50微升之量加入每一孔中,並置於搖擺器上,使接種之 細胞在含5% C〇2之暖箱内吸著60分鐘,再以每孔100微升之細胞生 長液補充。經72小時後,依參考文獻(鍾明華等,199〇,LPC組織培養 及兔化豬瘟疫苗免疫力比較,省衛畜試研報26: 15-22)中所述方法測定 病毒力價,惟第二抗體改用山羊抗豬IgGFITC標示抗體。 結果發現以無PCV1污染的PK-15-KL細胞增殖LPC-TS病毒,其 病毒之力價高達1078TCID5〇/毫升,較以往提高甚多。 疫苗之製備 自-80C冰櫃中取出該病毒原液,解凍後以6〇〇xg離心1〇分鐘,將 该上清液與保護劑(乳糖及PVp-K9〇)充分混合,使最終之組成1〇%為乳 糖、0·3%為PVP_9G ’紐將最終之半成品分裝於真空乾燥疫苗瓶中, 接著經冷凍真空乾燥而製成疫苗成品。 資例2 LPC_TS组織疫苗保存試驗 取LPC-TS組織疫苗四支,置於37^暖箱内。經過七天之後取出二 支’置於4C冰箱内,第14天時再取出二支。上述處理之疫苗及未處 理之疫苗二支各加入2毫升pBS溶解,相同處理之二支疫苗混合後, 依實例1中之方法測定其病毒力價。 /結果發現LPC-TS冷;東乾燥疫苗經於3rc暖箱内虐待試驗一週及二 週後’其病毒力價分別為4·8及3·9 1〇g 丁㈤一毫升,與未經處理者相 較下降不少(如表1所示)。 1241346 表1 :經冷凍乾燥及37°C處理後疫苗七價 期間 0週 -週 TCID5〇/毫升 6.2 4·8 3.9 實例3 LPC-TS组織疫苗内PCV 1之檢測 引子序列 此檢測中採用之引子序列係設計為可針對PCV 1之序列增幅出688 φ bp之PCR產物。引子序列如下示: F41 : 5,ATACGGTAGTATTGGAAAGGTAGGG3, B42 : 5,ACACTCGATAAGTATGTGGCCTTCT3, 病毒核酸之卒取 依據QUIGEN公司發展之DNA Mini Kit,取1〇〇微升之檢體加入 100微升之ATL緩衝液(Buffer ATL)及20微升之蛋白酶K (Proteinase K) ’置於56 C下作用至組織完全溶解’然後加入2〇〇微升之al緩衝 液’置於70 C下作用10分鐘’再加入200微升之無水酒精,使其震盈 15秒。然後,將樣品置入QUIGEN公司提供之QIAamp _ c〇lumn(含修 2毫升之收集管)内,離心6,000 X g約一分鐘,將QIAamp spin c〇lumn 置入一新的2毫升收集管,並加入500微升之AW1緩衝液,離心6,000 X g約一分鐘,再將QIAamp spin column置入一新的2毫升收集管,並 加入500微升之AW2緩衝液,使其超高速離心約一分鐘,接著將 QIAamp spin cohlmn置入一新的h5毫升收集管,並加入2〇〇微升之 AE緩衝液作用_分鐘,使其離心6,〇〇〇xg約一分鐘,最後將所萃取之 病毒核酸保存於。 聚合酶鏈反· 1241346 聚合酶鍵反應係依據 Mankertz et al· 1998. Identification of a protein essential for replication of porcine circovirus. J. Gen. Virol. 79: 21-227 以 及 Meeban et al· 1007. Sequence of porcine circovirus DNA: affinities with plant circovirus· J· Gen· Virol· 78: 221-227 中所述方法實施。 將6微升之抽取的DNA溶液預先混合於〇·65毫升離心管中之各種 反應溶液(引子20 μΜ 0.5微升、1·25 μΜ dNTP 8微升、10Χ Taq緩衝液 5微升及2.5U Taq DNA聚合酶),並加入DDW補至總體積為50微升 後,直接放入溫度控制器中進行PCR反應。反應條件如下:先以95。〇 進行12分鐘,再以95°C、20秒,57°C、20秒,72°C、45秒,共進行 42個週期;最後再以72它進行1〇分鐘。將於ιχ TAE緩衝液之反應產籲 物進行2%洋菜膠糖電泳分析,在電泳結束後浸泡於溴乙錠(EtBr)中, 並於子外線下觀察後照相。 以PBS 2毫升溶解LPC-TS組織疫苗後,進行如上述之程序,觀察 -到PCR電泳圖譜(圖1),其證實lpc-TS組織培養疫苗中並無pcv 1之 迷入,符合檢定標準。 資例4 LPC-TS组織培養活毒疫苗舆LPC-China兔化豬瘟疫苗之免疫保護效 _ 力比較 將十一週齡之第二代無特定病原菌(speciflc path〇gen free ; SpF)的豬 隻二十二頭分為七組,第一組四頭係免疫接種經PBS稀釋之1/100劑 ϊ的LPC-TS疫苗;第二組四頭係免疫接種經pBS稀釋之1/5〇〇劑量的 LPC-TS疫苗;第三組二頭係免疫接種經礦物油劑稀釋之1/1〇〇劑量的 LPC-TS疫苗;第四組二頭係免疫接種經礦物油劑稀釋之1/5〇〇劑量的 LPC-TS疫田,第五組四頭係免疫接種經pBs稀釋之丨八⑻劑量的 LPC-Chma疫苗;第六組四頭係免疫接種經pBs稀釋之ι/5〇〇劑量的 13 1241346 LPC-China疫苗;第七組二頭為對照組,分別注射pBs或礦物油劑各 一頭(如表2所示)。 兔2 : LPC-TS及LPC-China疫苗功效評估之實驗設計LPC-TS swine fatigue tissue. Receiving vaccine seed volume is first dissolved in Eagle's MEM (EMEM) cell maintenance solution (containing 2% bovine fetal serum) from the 812 batch of Lpc china rabbit pigs. Cancer vaccine 'Take the virus solution and inoculate PK-15 strain cells, soak it in a listening incubator for 90 to ⑽ minutes, and then wash her PK seven cells with EMEM three times before adding human emeiv cell maintenance solution. Place it in a 37 ° C warm box towel for three to four days, and place the aged pupal cells in a cold bed in a -8 ° C freezer. This culture is performed in the first to seventh generation of the culture method. The towels are all the same, but changed after the first generation _ without the first type strain of circular virus g-infected PK-15-KL strain cells to proliferate the virus and obtain [pc 丁 § 广 主 1241346 LPC-China virus first generation During the subculture period from the 17th generation, END (Exaltation of Newcastle Disease) and fluorescently labeled antibody staining techniques were used, and the clones were selected by limiting dilution method, in which the LPC-TS virus was used as EMEM cells. The maintenance solution was diluted 10-fold, and the 10-fold dilution was seeded into PK-15 cells in a 24-well culture plate. After 3 to 4 days, collect the virus solution, and then use fluorescent labeling antibody staining technology to determine the presence of fluorescence in the cells in the wells. Take the virus solution inoculated with the highest dilution of the virus solution and the fluorescence appears as seed poison to make LPC. -TS virus. Cell culture. PK-15-KL strain cells were cultured in cell culture flasks at a temperature of 36.5-37 C (50-80 ml of bovine fetal serum per 1000 ml, 0.7 g of NaHC03). And Eagle's MEM) for 72 to 96 hours, then discard the cell culture solution in the flask, and add an appropriate amount of PBS solution to wash the cell layer and discard the PBS. Then, after adding an appropriate amount of Trypsin Versene (TV) digestion solution, Place the culture flask into a 3r &c; c incubator to round the cells, shake or tap the culture flask to detach the cells. Pour the cell liquid into a sterile centrifuge tube and centrifuge at 300 X g for five minutes. Remove the supernatant After that, add a small amount of growth culture solution and disperse it with a sterile injection syringe, and then use cell culture solution to prepare a cell suspension of 30,000 cells / ml. The proliferation of the virus strain will have formed 60% -70% Monolayer of the above-mentioned pK_15_kl cell culture The liquid was discarded, and a seed virus (working seed vims) for LPC-TS production was inoculated into the cells with a virus amount of about 〇 丨 MOI (multiplicato 〇f infection), and the culture bottle was placed in a 37 ° C constant temperature chamber to make The cells were aspirated for 1.5 hours, and then a culture medium for virus proliferation (containing 10-20 ml of bovine fetal serum, 0.7 g of NaHC03 and Eagle, s MEM per 1,000 ml) was added, and the culture was continued at 37 ° c After 3 to 4 days in the thermostatic chamber, the infected cells are frozen and thawed once, and then the cells are separated by looo to remove cell debris. The supernatant was collected, and then filtered through a filter of 45 ° C. The obtained filtrate was the silk stock solution for vaccine production, and the virus stock solution was stored in a thief freezer for future use. LPC-TS virus potency test $ 1241346 diluted in cell growth medium (Eagle's MEM, which contains 5% bovine fetal serum (Hyclone), 100 u / ml penicillin, 100 pg / ml streptomycin and 10 mM HEPES, And PK-15-KL cells in 7.5% NaHC0 3) were first cultured in a 96-well plate, the next day when the cell monolayer reached 60-70% full, the cell culture solution was discarded, and then 10 The diluted virus solution was added to each well in an amount of 50 microliters per well, and placed on a rocker, so that the seeded cells were sucked in a warm box containing 5% CO2 for 60 minutes, and then 100 times per well was used. Replenish microliters of cell growth fluid. After 72 hours, the virus titer was determined according to the method described in the reference (Zhong Minghua et al., 199, LPC tissue culture and rabbit swine fever vaccine immunity comparison, Provincial Guarding Animal Trial Report 26: 15-22). The secondary antibody was changed to goat anti-pig IgGFITC labeled antibody. As a result, it was found that the proliferation of LPC-TS virus in PK-15-KL cells without PCV1 contamination had a virus power value of 1078TCID50 / ml, which was much higher than before. Preparation of vaccine The virus stock solution was taken out from the -80C freezer. After thawing, the virus was centrifuged at 600xg for 10 minutes. The supernatant was thoroughly mixed with the protective agent (lactose and PVp-K90) to make the final composition 10. % Is lactose and 0.3% is PVP_9G. The final semi-finished product is dispensed into a vacuum-dried vaccine bottle, and then frozen and vacuum-dried to make a finished vaccine product. Example 2 LPC_TS tissue vaccine preservation test Take four LPC-TS tissue vaccines and place them in a 37 ^ warm box. After seven days, two of them were taken out and placed in a 4C refrigerator, and two of them were taken out on the 14th day. The two vaccines treated as described above and the two untreated vaccines were each dissolved by adding 2 ml of pBS. After mixing the two vaccines of the same treatment, the virus titer was determined according to the method in Example 1. / Results found that LPC-TS was cold; after the East dry vaccine was abused in a 3rc incubator for one week and two weeks, its virus potency was 4. 8 and 3. 9 10 g of Ding Li 1 ml, and untreated Compared with this, it has dropped a lot (as shown in Table 1). 1241346 Table 1: Seven-valent period of vaccine after freeze-drying and 37 ° C TCID50 / ml 6.2 4 · 8 3.9 Example 3 Primer sequence for PCV 1 detection in LPC-TS tissue vaccine The primer sequence was designed to amplify a PCR product of 688 φ bp against the sequence of PCV 1. The primer sequences are shown below: F41: 5, ATACGGTAGTATTGGAAAGGTAGGG3, B42: 5, ACACTCGATAAGTATGTGGCCTTCT3. The viral nucleic acid was taken according to the DNA Mini Kit developed by QUIGEN, and 100 microliters of samples were added to 100 microliters of ATL buffer (Buffer ATL) and 20 microliters of Proteinase K ('56 ° C until tissue dissolves completely ') and then add 200 microliters of al buffer '70 ° C for 10 minutes' and then add 200 microliters Rise in absolute alcohol and shake for 15 seconds. Then, place the sample in the QIAamp_clumn (including 2ml collection tube) provided by QUIGEN, centrifuge at 6,000 X g for about one minute, and place the QIAamp spincolumin in a new 2ml collection tube. Add 500 microliters of AW1 buffer, centrifuge at 6,000 X g for about one minute, then place the QIAamp spin column into a new 2 ml collection tube, and add 500 microliters of AW2 buffer to ultracentrifuge for about one minute. Minutes, then put QIAamp spin cohlmn into a new h5 ml collection tube, add 2000 μl of AE buffer for _min, centrifuge it at 6,000 xg for about one minute, and finally extract the extracted Viral nucleic acid is stored in. Polymerase chain reaction · 1241346 The polymerase bond reaction is based on Mankertz et al. 1998. Identification of a protein essential for replication of porcine circovirus. J. Gen. Virol. 79: 21-227 and Meeban et al. 1007. Sequence of porcine circovirus DNA: affinities with plant circovirus · J · Gen · Virol · 78: 221-227. 6 microliters of the extracted DNA solution were premixed in various reaction solutions in a 65-mL centrifuge tube (primers 20 μM 0.5 μl, 1.25 μM dNTP 8 μl, 10 × Taq buffer 5 μl, and 2.5U Taq DNA polymerase), and add DDW to make up a total volume of 50 microliters, and directly put it into the temperature controller for PCR reaction. The reaction conditions are as follows: 〇 12 minutes, then 95 ° C, 20 seconds, 57 ° C, 20 seconds, 72 ° C, 45 seconds, for a total of 42 cycles; finally, 72 minutes for 10 minutes. The reaction product of ιχ TAE buffer solution was subjected to 2% agarose gel electrophoresis analysis. After the electrophoresis was completed, it was immersed in ethidium bromide (EtBr) and observed under the outside line and photographed. After dissolving the LPC-TS tissue vaccine in 2 ml of PBS, the procedure as described above was performed, and the PCR electrophoresis pattern was observed (Fig. 1), which confirmed that the pcv 1 in the lpc-TS tissue culture vaccine was not obsessed with the test standard. Example 4 LPC-TS tissue culture live virus vaccine and the immunoprotective effect of LPC-China rabbit swine fever vaccine _ comparison of the eleven-week-old second-generation speciflc pathogen free (SpF) Twenty-two pigs were divided into seven groups. The first group of four animals was immunized with 1/100 doses of LPC-TS vaccine diluted with PBS; the second group of four animals was immunized with 1/5 of pBS diluted. 〇 dose of LPC-TS vaccine; the third group of two-headed immunization was diluted with mineral oil 1/1100 dose of LPC-TS vaccine; the fourth group of two-headed immunization was diluted with mineral oil 1/100 In the 500-dose LPC-TS epidemic field, the fifth group of four-headed immunizations was diluted with pBs and the eight-dose dose of LPC-Chma vaccine; the sixth group of four-headed immunizations was diluted with pBs at / 5/5. The dose of 13 1241346 LPC-China vaccine; the second group of the seventh group was the control group, and each was injected with pBs or mineral oil (as shown in Table 2). Rabbit 2: Experimental design of efficacy evaluation of LPC-TS and LPC-China vaccines
組 豬隻數目 疫苗 1 4 稀釋於 PBS 之 1/100 LPC-TS - 2 4 稀釋於 PBS 之 1/500 LPC-TS 3 2 稀釋於 OE 之 1/100 LPC-TS 4 2 稀釋於 OE 之 1/500 LPC-TS 5 4 稀釋於 PBS 之 1/100 LPC-China 6 4 稀釋於 PBS 之 1/500 LPC-China 7 2 PBS 或 OE 經疫苗免疫接種後二週,以之ALD豬瘟強毒(由行政院農 委會豕畜衛生試驗所之動物用藥品檢定分所供應)攻擊二十二頭豬隻, 攻毒後每日測量肛溫且觀察症狀,並於3、7、1〇及17天採集血液及 採取口腔棉拭’檢測是否有病毒血症(viremia)或排毒(shedding)。 實驗結果 經攻毒後兩天内,除了經免疫接種1/1〇〇及1/5〇〇劑量的LpC-TS 疫苗之豬隻之體溫略為升高(<40.5。〇以外,其他豬隻皆保持正常,表 現對攻毒之耐受性。而對照組豬隻二頭在攻毒後四天體溫上升至41.5 C,其中注射PBS之對照組豬隻在攻毒後13天發病死亡,另一頭則呈 現嚴重症狀’瀕臨死亡,如圖2所示。 此外,所有經免疫接種LPC_TS或LPC_China疫苗之豬隻,無論是 1/100或1/500劑量,再攻毒後均未出現病毒血症,亦未能從豬隻的口 水中分離出病毒。對照組豬隻則從攻毒後三天(3 Dpc)起均可檢驗出病 f., 14 1241346 毒血症及排毒(如表3所示)。 表3 :攻毒後經免疫接種及對照組豬隻發現有病毒血症及排毒之數目 豬隻 疫苗 _碑毒血症數目/排毒數目_攻毒 數目_ 〇DPC 3 DPC 7DPC 10DPC 17DPC 結果Number of pigs in the group: vaccine 1 4 diluted 1/100 LPC-TS in PBS-2 4 diluted 1/500 LPC-TS 3 in PBS 3 2 diluted 1/100 LPC-TS 4 in OE 1 2 diluted 1/100 in OE 500 LPC-TS 5 4 1/100 LPC-China 6 4 diluted in PBS 1 4/500 LPC-China 7 2 diluted in PBS or OE Two weeks after vaccination, ALD swine fever (from (Supplied by the Animal Medicine Testing Branch of the Agricultural Committee of the Executive Yuan and the Animal Health Test Institute) Attacked 22 pigs, measured the anal temperature and observed the symptoms daily after the challenge, and on 3, 7, 10, and 17 days Blood was collected and oral swabs were taken to detect viremia or shedding. Experimental results Two days after challenge, except for pigs immunized with LpC-TS vaccine at 1/100 and 1/500 doses, the body temperature increased slightly (<40.5.00, all other pigs were It remained normal and showed tolerance to challenge. However, the temperature of the two pigs in the control group rose to 41.5 C four days after challenge, and the control group of pigs injected with PBS died and died on the 13th day after challenge. There are severe symptoms' on the verge of death, as shown in Figure 2. In addition, all pigs immunized with LPC_TS or LPC_China vaccine, no matter whether the dose is 1/100 or 1/500, did not develop viremia after re-challenge. The virus could not be isolated from the saliva of the pigs either. The control group of pigs could detect the disease from three days after challenge (3 Dpc) f., 14 1241346 Toxemia and detoxification (as shown in Table 3) Table 3: Number of viremia and detoxification found in pigs immunized and control group after challenge. Pig vaccine_Number of toxins / Number of detoxification_Number of challenge_ 0 DPC 3 DPC 7DPC 10DPC 17DPC Results
〇/〇 0/0 NT/0 0/NT 4 S〇 / 〇 0/0 NT / 0 0 / NT 4 S
4 稀釋於PBS之 0/0 1/100 LPC-TS 4 稀釋於PBS之 1/500 LPC-TS 2 稀釋於OE之 1/100 LPC-TS 2 稀釋於OE之 1/500 LPC-TS 4 稀釋於PBS之 1/100 LPC-China 4 稀釋於PBS之 1/500 LPC-China 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/04 diluted 0/0 1/100 LPC-TS in PBS 4 diluted 1/500 LPC-TS in PBS 2 diluted 1/100 LPC-TS in OE 2 diluted 1/500 LPC-TS in OE 4 diluted in 1/100 LPC-China 4 of PBS Diluted 1/500 LPC-China of PBS 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0 / 0 0/0 0/0 0/0 0/0
ΝΤ/0 0/ΝΤ 4S ΝΤ/0 0/ΝΤ 2S ΝΤ/0 0/NT 2S ΝΤ/0 0/NT 4S ΝΤ/0 0/NT 4SNT / 0 0 / NTP 4S NT / 0 0 / NTP 2S NT / 0 0 / NT 2S NT / 0 0 / NT 4S NT / 0 0 / NT 4S
結果顯不經1/100或1/500劑量之稀釋於pBS或〇E乳液中的本發 明之LPC-TS組織培養疫苗接種後的免疫豬隻均耐過,其受到完全之保 護,未出現任何臨床症狀且無病毒血症,其臟器組織中以^^⑶檢測 亦未發現齡絲滅,顯和與啦心⑽統齡疫苗相當之免 疫保護效力。姆地,舰_隻則發病死亡,僅有—職射稀釋於 OE乳液的疫苗之豬隻似有輕微之非特異性抵抗力。The results showed that the immune pigs that had not been inoculated with the LPC-TS tissue culture vaccine of the present invention diluted in pBS or oE emulsion at a 1/100 or 1/500 dose were all tolerated, and they were completely protected without any occurrence. With clinical symptoms and no viremia, ^^ (3) was not detected in the organ tissues, which showed an immunoprotective effect comparable to that of the palpitative age vaccine. By the way, warships have died of illness, and only-pigs who have shot the vaccine diluted in OE emulsion seem to have a slight non-specific resistance.
15 1241346 經免疫接種LPC-China兔化豬瘟疫苗輿LPC-TS組織培養活毒疫苗之豬 隻產生之中和抗體測定 上述豬隻經LPC-TS或LPC-China疫苗免疫接種後一週及二週,以 及在攻毒後二週,檢測豬隻(包括對照組)血清之中和抗體,檢測之方法 係為間接螢光標示抗體檢測法,依據參考文獻(鍾明華等,1990,LPC 組織培養及兔化豬瘟疫苗免疫力比較,省衛畜試研報26: 15-22 ;及 Terpstra,C·,et al” 1984. The neutralizing peroxidase-linked assay for detection of antibody against swine fever virus. Vet. Microbiol. 9: 113-120) 中所述方法進行,第二抗體亦改用山羊抗豬IgGFITC標示抗體。 實驗結果顯示經LPC-TS及LPC-China疫苗免疫接種後一週(pvw 1),未測得中和抗體之產生,但在疫苗免疫後二週(PVW2)始可測得抗 體,且1/100劑量之疫苗免疫豬隻產生之抗體較1/500劑量者為高。在 攻毒後二週,免疫豬隻產生之中和抗體均大幅上升,如表4所示。 表4 ·經疫苗接種及攻毒後諸隻之血清中和抗體效價 豬隻數 疫苗 SN效價幾何平均值 g PVW0* PVW1 PVW2 PCW2 4 稀釋於PBS之 1/100 LPC-TS 0 0 32.2 197.2 4 稀釋於PBS之 1/500 LPC-TS 0 0 17.7 2,041.7 2 稀釋於OE之 1/100 LPC-TS 0 0 53.7 609.5 2 稀釋於OE之 1/500 LPC-TS 0 0 8.1 305.5 4 稀釋於PBS之 1/100 LPC-China 0 0 41.2 609.5 4 稀釋於PBS之 1/500 LPC_China 0 0 12.4 609.5 1 對照組(PBS) 0 0 0 16 *PVW : 免疫接種後之週數 ;PCW : 攻毒後之週數 Φ-, 16 1241346 發瘟病毒核酸之檢測 试驗之豬隻在攻毒後17天全部犧牲,包括二十二頭經免疫接種疫 苗之豬隻及瀕死對照豬隻均予犧牲,解剖觀察肉眼病灶,採取脾、肺、 腦、扁桃腺、腸間淋巴結,做成乳劑後,以PK-15-KL細胞分離豬瘟病 毒,並以反轉錄聚合酶鏈反應(RT-PCR)檢測豬瘟病毒核酸(ALD強毒)。 試驗方法係參考 Greiser-Wilke et al· 2000· Molecular epidemiology of a large classical swine fever epidemic in European Union in 1997-1998. Vet.15 1241346 Neutralizing antibodies produced by pigs vaccinated with LPC-China rabbit swine fever vaccine and LPC-TS tissue culture live virus vaccine Determination of the above-mentioned pigs one week and two weeks after immunization with LPC-TS or LPC-China vaccine And two weeks after challenge, the neutralizing antibodies in the serum of pigs (including the control group) were detected. The detection method was the indirect fluorescent labeling antibody detection method, based on references (Zhong Minghua et al., 1990, LPC tissue culture and rabbits). Comparison of immunity against swine fever vaccine, Provincial Trial Animal Research Report 26: 15-22; and Terpstra, C., et al "1984. The neutralizing peroxidase-linked assay for detection of antibody against swine fever virus. Vet. Microbiol. 9 : 113-120), and the second antibody was changed to goat anti-pig IgGFITC labeled antibody. The experimental results showed that one week after the immunization with the LPC-TS and LPC-China vaccines (pvw 1), no neutralization was detected. The production of antibodies, but the antibodies can be measured two weeks after the vaccine immunization (PVW2), and the antibody produced by the pigs immunized with the vaccine at a rate of 1/100 is higher than those with a dose of 1/500. Two weeks after the challenge, the immunization Large neutralizing antibodies produced by pigs The increase, as shown in Table 4. Table 4 • Serum neutralizing antibody titers of pigs after vaccination and challenge challenge Geometric number of pigs SN titer Geometric mean PVW0 * PVW1 PVW2 PCW2 4 Diluted in PBS 1 / 100 LPC-TS 0 0 32.2 197.2 4 1/500 LPC-TS diluted in PBS 0 0 17.7 2,041.7 2 1/100 LPC-TS diluted in OE 0 0 53.7 609.5 2 1/500 LPC-TS diluted in OE 0 0 8.1 305.5 4 1/100 LPC-China diluted in PBS 0 0 41.2 609.5 4 1/500 LPC_China diluted in PBS 0 0 12.4 609.5 1 Control group (PBS) 0 0 0 16 * PVW: Weeks after immunization ; PCW: Weeks after challenge Φ-, 16 1241346 Pigs tested for pestilence virus nucleic acid were sacrificed 17 days after challenge, including 22 immunized pigs and dying control pigs All were sacrificed, the macroscopic lesions were dissected and observed, and the spleen, lung, brain, tonsil, and intestinal lymph nodes were taken to make an emulsion. The swine fever virus was isolated by PK-15-KL cells and reverse transcription polymerase chain reaction ( RT-PCR) detection of classical swine fever virus nucleic acid (ALD strong). For the test method, refer to Greiser-Wilke et al. 2000. Molecular epidemiology of a large classical swine fever epidemic in European Union in 1997-1998. Vet.
Microbiol· 77: 17_27 以及 Lorena et al. 2001. Classical swine fever virus (C strain) distribution in organ samples of inoculated piglets. Vet. Microbiol. 81: 1-8中所述之方法進行,並稍加修改。 ⑴引子序列: 依據Genbank所刊載之豬瘟病毒基因序列,經比較不同基因型病毒 間之差異後,選擇NS5B之區域設計增幅引子,此引子係為通用引子 (universalprimers),即其可適用於所有基因型之豬瘟病毒。引子序列如 F : GACACAACCAACTTCCACC R : TTCTGCTTCACCCACTTATA (2)核酸之卒取: 將上述豬隻的器官或組織製得之乳劑200微升加入1毫升之Triz〇I 總RNA萃取試劑中,且以震盪器混合十五秒,於室溫下靜置五分鐘後, 加入200微升氯仿,混合十五秒後靜置三分鐘,再以ι2,〇〇()叩以分鐘 於4艺離心十五分鐘後,萃取其上清液置處理過之乾淨微量離心管,加 入等體積之異丁醇,並使其上下搖晃混合均勻後,於室溫下靜置十分 鐘。然後,以12,000卬111/分鐘於4。(:離心十五分鐘後,除去所有溶液, 並於室溫下烘乾十至十五分鐘,加入適當體積之無的二次水溶 17 1241346 解沉積物並冷藏備用。 (3)反轉錄聚合酶鏈反應(RT-PCR) 取已製備好之核酸樣本3-5微升,加入-對特異性引子(2〇㈣、職 反應液、Rnasin (Promega) 2U、AMV反轉錄酵素听瓣㈣犯、聚合 酵素及dNTP (25 mM) ’再將處理過之二次水補滿至5〇微升。於轨辦 反應器_ 9600)中係以收下反應45分鐘之後進行pcR反應,其條 件為94°C下30秒、坑下3〇秒及饥下丨分鐘,連續循環如次後, 將反應液以1.2%洋菜膠進行電泳分析以檢測其產物。 貫驗結果顯不所有經疫苗免疫接種之緒隻的臟器組織中皆未分離 出豬疲病毒,且RT-PCR之結果亦全為陰性;二騎照_隻之齡中_ 均可分離出豬痕病毒’ RlVpCR結果亦為陽性,但注射〇E之一對照組 豬隻之臟器内病毒含量遠較另一頭注射PBS者少,且其腸間淋巴結之 RT-PCR結果亦為陰性,未能以RT_pCR檢出緒疽病毒核酸,如表5及 6中所示。 18 1241346 表5 :攻毒後經免疫接種及對照組豬隻中分離出病毒 豬隻 疫苗 陽性數目/陰性數目 數目 脾 肺 腦 扁桃腺 腸間淋巴結 4 稀釋於PBS之 1/100 LPC-TS 0/4 0/4 0/4 0/4 0/4 4 稀釋於PBS之 1/500 LPC-TS 0/4 0/4 0/4 0/4 0/4 2 稀釋於OE之 1/100 LPC-TS 0/2 0/2 0/2 0/2 0/2 2 稀釋於OE之 1/500 LPC-TS 0/2 0/2 0/2 0/2 0/2 4 稀釋於PBS之 1/100 LPC-China 0/4 0/4 0/4 0/4 0/4 4 稀釋於PBS之 1/500 LPC-China 0/4 0/4 0/4 0/4 0/4 1 對照組(PBS) +++* +++ +++ +++ NT 1 對照組(OE) ++ + + + + • *螢光斑數目之記分 • NT :未檢測 1241346 RT-pcR對攻至^复器官之豬瘟病毒核^洽測 豬隻 疫苗__陽性數目 脾 肺 腦 扁桃fl会 ---— 淋巴結 0 4 稀釋於PBS之 1/100 LPC-TS 0 0 0 0 4 稀釋於PBS之 1/500 LPC-TS 0 0 0 0 0 2 稀釋於OE之 1/100 LPC-TS 0 0 0 0 0 2 稀釋於OE之 1/500 LPC-TS 0 0 0 0 0 4 稀釋於PBS之 1/100 LPC-China 0 0 0 0 0 4 稀釋於PBS之 1/500 LPC-China 0 0 0 0 0 1 對照組CPBS) 1 1 1 1 1 1 對照組(OE) 1 1 1 1 1 Π —上述實驗之結果皆齡,本發敗LPC_TS株兔化豬缝織疫苗中 無第-型_狀病毒(PCV 1)之污染’且免疫接種該疫苗之豬隻,經野 外型(ALD)強毒之攻擊後,其產生之中和抗體皆顯著增加,未出現病毒 血症’且其臟器内亦未能檢出豬瘟病毒核酸。相較於LPC-China兔化 豬瘟疫苗,本發明之LPC_TS組織培養疫苗顯示出相當良好之保護效 力。 jtfeLll. 稀釋液對於LPC-TS兔化豬瘟疫苗之影響 20 1241346 \、LPC-TS株病毒與保護劑以j ·· *之比例混合後,以每瓶2毫升分裝 於冷滚乾内,接著冷魏燥之。取出六支試製疫苗,分取純水、 PBS ^ 5%葡萄糖各溶解二支疫苗,經充分混合後二支疫苗再分成二 、’且刀置於5 c冰箱及32〇c暖房内,並於4小時及小時後測定阳 及病毒力價。 結果 -本务明的LPC-TS兔化豬痕疫苗溶於純水、pBS及5%葡萄糖中在不 同/皿度下之pH值變化係示於表7中。純水、pBS及5%葡萄糖原液之 pH值刀別為5·75、716及3 86,其中疫苗以純水稀釋之阳值偏低, 但=5/〇葡萄糖作為稀釋液之阳值則更低。經pBs溶解之疫苗可* U · J日守内保持相當穩定之ρΗ值pm);以純水及5%葡萄糖溶解之疫苗 的pH值均較原液為高,但後者阳值仍然偏低 ,且其在12小時後更降 低至pH 5·15,對於病毒可能有不利之影響。 由依螢光標示抗體染色法測定病毒力價之結果(如表8所示)可知, LPC-TS株病毒在冷凍乾燥過程中降低〇·7 1〇細丁㈤^毫升,以純水及 ^浴解後12小時内病毒力價僅降低〇·1 logioTCHV毫升,且維持穩 定。但是,經5%葡萄糖溶解者,在室溫中(R°C)甫經溶解之病毒力價為 4·〇5 l〇g10 TCHV毫升,較以純水及pBS溶解者為低,且其在u小時 内會大幅降低至$ 2·8〇 lGgiQ TCID5()/毫升。 ❿ —:溶解稀釋液之LPC-TS疫苗在不同pH值變化 稀釋液 5°C 32〇Γ 0小時 4小時 12小時 4小日寺 12小時 DDW 6.80 7.10 6.96 6.71 6.39 PBS 7.20 7.24 7.18 7.25 7.12 5%葡萄糖 5.26 5.64 5.68 5.32 5.15 21 1241346 _____ 4小時 32〇C 12小時 4.05 4.18 4.05 4.18 <2.80 <2.80 表8 ·溶解於不同稀釋液之LPC-TS疫苗在不同條件下之穩定性(病毒力 價,以考升表示) 'Microbiol. 77: 17_27 and Lorena et al. 2001. Classical swine fever virus (C strain) distribution in organ samples of inoculated piglets. Vet. Microbiol. 81: 1-8. ⑴ Primer sequence: Based on the swine fever virus gene sequence published by Genbank, after comparing the differences between different genotype viruses, select the NS5B region to design the amplified primers. This primer is universal primers, that is, it can be applied to all Genotype of swine fever virus. Primer sequences such as F: GACACAACCAACTTCCACC R: TTCTGCTTCACCCACTTATA (2) Nucleic acid stroke: 200 microliters of the emulsion prepared from the organs or tissues of the above pigs was added to 1 ml of Trizoi total RNA extraction reagent, and mixed with a shaker Fifteen seconds, after standing at room temperature for five minutes, add 200 microliters of chloroform, mix for 15 seconds and let stand for three minutes, and then centrifuge at 4 ° C for 15 minutes at 2.00 (). The supernatant was extracted and placed in a clean micro-centrifuge tube, and an equal volume of isobutanol was added, and the mixture was shaken up and down to mix uniformly, and then allowed to stand at room temperature for ten minutes. Then, set it at 4 at 12,000 卬 111 / min. (: After 15 minutes of centrifugation, remove all solutions, and dry at room temperature for 10 to 15 minutes. Add an appropriate volume of secondary water-soluble 17 1241346 to dissolve the sediment and refrigerate for future use. (3) Reverse transcription polymerase Chain reaction (RT-PCR) Take 3-5 microliters of the prepared nucleic acid sample, add-pair of specific primers (202, reaction solution, Rnasin (Promega) 2U, AMV reverse transcriptase, listening valve offender, Polymerase and dNTP (25 mM) 'Fill up the treated secondary water to 50 microliters. In the orbital reactor_ 9600), the reaction is performed after receiving the reaction for 45 minutes, and the condition is 94. After 30 seconds at 30 ° C, 30 seconds at the pit, and 丨 minutes at the hunger, the reaction solution was subjected to electrophoresis analysis with 1.2% agar gelatin to detect the products after continuous cycling. The results of the test showed that all the vaccines were not immunized. Porcine fatigue virus was not isolated from the organ tissues of Xuzhi, and the results of RT-PCR were all negative; Porcine scar virus could be isolated from the two riding photos _ only in the age of _, and the RlVpCR result was also positive, However, the virus content in the viscera of the control group of pigs injected with 0E was much less than that of the other group injected with PBS. The results of RT-PCR of the interstitial lymph nodes were also negative, and the nucleic acid of gangrene virus could not be detected by RT_pCR, as shown in Tables 5 and 6. 18 1241346 Table 5: Isolation from challenged pigs after immunization and control Number of virus pigs positive / negative number of spleen, lung, brain, tonsil, and intestinal lymph nodes 4 diluted 1/100 in PBS LPC-TS 0/4 0/4 0/4 0/4 0/4 4 diluted 1 in PBS / 500 LPC-TS 0/4 0/4 0/4 0/4 0/4 2 1/100 diluted in OE LPC-TS 0/2 0/2 0/2 0/2 0/2 2 diluted in OE 1/500 LPC-TS 0/2 0/2 0/2 0/2 0/2 4 diluted 1/100 LPC-China 0/4 0/4 0/4 0/4 0/4 4 diluted in PBS 1/500 LPC in China PBS 0/4 0/4 0/4 0/4 0/4 1 Control group (PBS) +++ * +++ +++ +++ NT 1 Control group (OE) ++ + + + + • * Scores of the number of fluorescent spots • NT: 1241346 RT-pcR pair has not been detected for the swine fever virus nucleus of ^ complex organs ^ Negotiation of pig vaccines __ Positive number of spleen, lung, brain, almond fl ----- Lymph node 0 4 1/100 LPC-TS diluted in PBS 0 0 0 0 4 1/500 LPC-TS diluted in PBS 0 0 0 0 0 2 1/100 LPC-TS diluted in OE 0 0 0 0 0 2 1/500 LPC-TS diluted in OE 0 0 0 0 0 4 1/100 LPC-China diluted in PBS 0 0 0 0 0 4 1/500 LPC-China diluted in PBS 0 0 0 0 0 1 Control group (CPBS) 1 1 1 1 1 1 Control group ( OE) 1 1 1 1 1 Π — The results of the above experiments are all old, and the rabbits of the LPC_TS strain that failed to produce the virus were not contaminated with type-like virus (PCV 1), and pigs immunized with the vaccine After being attacked by ALD, its neutralizing antibodies increased significantly, no viremia occurred, and no swine fever virus nucleic acid was detected in its organs. Compared with the LPC-China rabbit swine fever vaccine, the LPC_TS tissue culture vaccine of the present invention shows quite good protective effect. jtfeLll. The effect of the dilution on the LPC-TS rabbit swine fever vaccine 20 1241346 \, the LPC-TS strain virus and the protective agent were mixed in the proportion of j · · *, and 2 ml of each bottle was dispensed in cold tumble dry, Then cold and dry. Take out six trial vaccines, divide pure water, PBS ^ 5% glucose and dissolve each of the two vaccines. After thorough mixing, the two vaccines are divided into two, and the knife is placed in a 5c refrigerator and a 32oC warm room. The positivity of positivity and virus was measured after 4 hours. Results-The pH change of the present LPC-TS rabbitized pig scar vaccine dissolved in pure water, pBS and 5% glucose at different levels is shown in Table 7. The pH values of pure water, pBS and 5% glucose stock solutions are 5.75, 716, and 3 86. The positive value of the vaccine diluted with pure water is lower, but the positive value of = 5 / 〇 glucose as the diluted solution is even more. low. The vaccine dissolved with pBs can maintain a fairly stable pH value in U.S.J .; the pH value of the vaccine dissolved in pure water and 5% glucose is higher than the original solution, but the positive value of the latter is still low, and It lowers to pH 5.51 after 12 hours, which may have an adverse effect on the virus. From the results of measuring the viability of the virus according to the fluorescent antibody staining method (as shown in Table 8), it can be seen that the LPC-TS strain virus was reduced by 0.7 · 10 μ㈤ in the freeze-drying process, and purified water and bath were used. The virus titer only decreased by 0.1 logioTCHV ml within 12 hours after lysis, and remained stable. However, for those who dissolve with 5% glucose, the virus valence at room temperature (R ° C) is 4 · 05 lOg10 TCHV ml, which is lower than those dissolved with pure water and pBS. Within u hours, it will be greatly reduced to $ 2.80GgiQ TCID5 () / ml. ❿ —: LPC-TS vaccine dissolved in diluent at different pH values. Diluent 5 ° C 32 ° 0 hours 4 hours 12 hours 4 Xiaoriji 12 hours DDW 6.80 7.10 6.96 6.71 6.39 PBS 7.20 7.24 7.18 7.25 7.12 5% Glucose 5.26 5.64 5.68 5.32 5.15 21 1241346 _____ 4 hours 32 ° C 12 hours 4.05 4.18 4.05 4.18 < 2.80 < 2.80 Table 8Stability of LPC-TS vaccine dissolved in different dilutions under different conditions (viral potency) , Expressed as a test promotion) '
5°C 稀釋液 4小時 12小時 4.18 4.18 4.18 4.18 3.55 3.55 DDW 4.30 PBS 4.30 5%葡萄糖 4.05 由上述結果可知,以5%葡萄糖溶解冷凍乾燥豬瘟疫苗後之pH值甚鲁 低’且LPC-TS組織疫苗在5%葡萄糖溶液中最不安定,因此,磷酸鹽 綾衝液及純水均可作為LPCVrs組織疫苗之稀釋液,但為了不影響注射 部位組織細胞之生理狀況,以磷酸鹽緩衝液作為稀釋液最適宜。 膏例6丄 LPC-China兔化豬瘟疫苗舆LPC_TS组織培養疫苗之田間比較試驗 化緒癌疫苗之安全性 選定雲林絲畜赫防治所轄區内之二養豬場,在第—場内實施三Diluted at 5 ° C for 4 hours and 12 hours 4.18 4.18 4.18 4.18 3.55 3.55 DDW 4.30 PBS 4.30 5% glucose 4.05 From the above results, it can be seen that the pH value after dissolving the freeze-dried swine fever vaccine with 5% glucose is extremely low 'and LPC-TS Tissue vaccine is the most unstable in 5% glucose solution. Therefore, phosphate mash and pure water can be used as the dilution of LPCVrs tissue vaccine, but in order not to affect the physiological condition of tissue cells at the injection site, phosphate buffer is used as the dilution. Liquid is most suitable. Paste Example 6: LPC-China Rabbit Swine Fever Vaccine and LPC_TS Tissue Culture Vaccine Field Comparative Test The safety of the serocarcinoma vaccine was selected as the second pig farm in the area under the control of Yunlin Siguhe Prevention and Treatment Center. three
週齡加六·兩次免疫以及六職—次免疫之兩種免疫讎方式,分 別^疫注射LPC_TS及LPC_China兔化豬疲疫苗;在另一場内,實施哺 乳前加六週齡兩次免疫以及哺乳前—次免疫之兩種免疫接種方式,亦 分別注射LPC_TS及LPC_china統豬奴苗。_經上述四種方式免 疫接種的豬隻之生長情形。 結果,經免疫接種LPC-TS及LPC_China兔化豬疲疫苗之緒隻( 12,〇〇〇頭小豬)中,未發現任何不良反應,包括部分純種諸在内,經 雜種之小豬狂常發纽生長,故齡出LPC_TS輯培養疫苗極 女全0 22 1241346 疫接種一次衫 40頭以三週齡加六週齡各免疫接種—次與六週 Γ=Γ寺自上述養猪場中蹲回,在攻毒前適應期間已_ 土頁二餘38頭主以及對照組豬隻係以肌肉注射2 〇 χ 1〇4叫之強 骨攻权’攻毋後母日測量豬隻之體溫且觀察臨床 — ^楚過峨以上時即採取口腔棉拭及血液,物卿毒及;毒 血症0 試驗結果顯示經ALD強毒攻擊後,試驗豬隻陸魏死4頭,而有 3隹4頭耐過。四頭繁死之豬隻均出現發燒(4〇 m,於解剖後認定該等豬· 又糸因AP而死亡,且有病毒血症,但無豬瘦病灶。%頭财過之褚隻 大部分^發燒現象,於解剖後發現β頭豬隻有Ap之病灶,ό頭豬 隻有病毒血症,但未發現豬盘病灶;另外b頭豬隻正常,未發現处 之病絲病毒血症。然而,四麟照組小酬發高燒(411以上), 且陸績發病壯,其皆有縣血症,但其巾三職隻呈典型讀麵 - 灶,另一頭豬隻無豬痕病灶(表9)。 表9 ·、、二LPC-Chma及LPC-TS豬瘟疫苗免疫接種之豬隻於攻毒後之社 果Two ages of immunizations at six weeks of age plus six-time immunizations and six-time-second immunizations, respectively, were injected with LPC_TS and LPC_China rabbitized pig fatigue vaccine; in another session, two immunizations at six weeks of age before breastfeeding and The two immunization methods of pre-lactation-primary immunization were also injected with LPC_TS and LPC_china traditional pig slaves. _ Growth of pigs immunized by the four methods described above. As a result, no adverse reactions were found in the LPC-TS and LPC_China rabbit pig strain vaccines (12,000 piglets) after immunization, including some purebred piglets. Chang Fa Niu grows up, so the age of LPC_TS series culture vaccine extremely female full 0 22 1241346 40 shirts once inoculated with vaccination at the age of three weeks plus six weeks of age-once and six weeks Γ = Γ Temple from the above pig farm Squat back, during the adaptation period before the challenge, _______________, 38 other main and control pigs were intramuscularly injected with a strong bone attack of 20 × 104, and the body temperature of the pigs was measured on the mother day. And observe the clinical — ^ Oral swabs and blood were taken when Chu was too high, and poisonous and poisonous; Toxemia 0 The test results showed that after the ALD poisoning attack, the test pig Lu Wei died 4 and 3 4 heads withstand. All four dead pigs developed fever (40m, after the dissection, they were determined to have died of AP, and had viremia, but no lean lesions in the pigs. Part of the fever phenomenon, after the dissection, it was found that the beta pigs had only Ap lesions, and the pigs had only viremia, but no pig disc lesions were found; in addition, the b pigs were normal and no diseased filamentous virus disease was found. However, The Shilinzhao group had a high fever (more than 411) and a strong onset of Lu Ji. All of them had county bloodemia, but their three positions only showed typical reading surface-focal, and the other pig had no pig-marked lesions (Table 9) Table 9: Social results of pigs vaccinated with LPC-Chma and LPC-TS swine fever vaccine after challenge
使用疫苗計晝__ 豬隻數目(患有病毒血症)Use vaccine to count day __ number of pigs (with viremia)
因ΑΡ死亡患有ΑΡ 正常 因豬瘟死 0 0 0 0Death due to AP is normal AP death due to swine fever 0 0 0 0
LPC-TS 3週+6週 1(1) 4(3) 4 LPC-TS 6週 1 8(1) 1 LPC-China 3週+6週 1 5(2) 4 LPC-China 6週 id) 2 6 23 !241346 迦£I^LPC-China疫苞對_魅_前力这趣 IL盖免疫接種一次之小豬的免疫保謹效力 與前述試驗類似,40頭以哺乳前加六週齡各免疫接種一次與哺乳前 免疫接種-次之小猪,於2.5月齡時自上述養緒場中購回,但在購回前 -天、輸運當天及到達次日分別在緒隻中注射拜有利(Baytril,如㈣】 毫升/10公斤體重’用以預防AP之感染。以2 0 x 1〇4 LD5〇之ald強 毒攻擊豬隻及賴域f,攻毒魏日測量豬隻之體溫且觀察臨床症 狀’ -旦豬隻之體溫超過40.5°c以上時即採取口腔棉拭及血液,用以 測定排毒及病毒血症。 肇 試驗結果顯示經ALD強毒攻擊後,所有經免疫接種疫苗(包括 LPC-Chma兔化豬瘂疫苗及LPC_TS組織培養活毒疫苗)之猪隻皆正常 财過,且未發職毒血症及排毒。二珊·朴酬在攻紐二天體 溫即上昇至41°C,且均發病死亡,亦可從血液及口腔中檢出病毒,於 解剖後發現典型之豬瘟病灶(如圖3及表1〇中所示)。 表10 ·經LPC-Chma及LPC-TS豬瘟疫苗免疫接種之豬隻於攻毒後之LPC-TS 3 weeks + 6 weeks 1 (1) 4 (3) 4 LPC-TS 6 weeks 1 8 (1) 1 LPC-China 3 weeks + 6 weeks 1 5 (2) 4 LPC-China 6 weeks id) 2 6 23! 241346 迦 I ^ LPC-China epidemic bud pair _ charm_qianli this fun IL cover immunized piglets once immunized with the same effect as the previous test, 40 pigs were vaccinated before breastfeeding plus six weeks of age Piglets once inoculated and immunized before breastfeeding-followed by piglets were repurchased from the above-mentioned breeding ground at 2.5 months of age, but injections were given in the only place before the day of repurchase, the day of transport, and the day after arrival. (Baytril, Rugao) ml / 10 kg body weight 'is used to prevent AP infection. Pigs and Lai Yu f are attacked with ald strong poison of 20 x 104 LD50, and the temperature of the pigs is measured by Wei Ri attack and Observe clinical symptoms'-When the body temperature of the pigs exceeds 40.5 ° c, oral swabs and blood are taken to determine detoxification and viremia. The results of the test show that all vaccinated ( The pigs including LPC-Chma rabbit pig pupae vaccine and LPC_TS tissue culture live virus vaccine) were all normal wealth, and had not developed toxemia and detoxification. Ershan Park paid the temperature in the second day of the attack. The temperature rose to 41 ° C, and all died of disease. The virus was also detected from the blood and oral cavity, and typical swine fever lesions were found after dissection (as shown in Figure 3 and Table 10). Table 10 Chma and LPC-TS swine fever vaccine
結果 使用疫苗接種疫苗計畫 試驗 LPC-TS 哺乳前+6週 10 LPC-TS 哺乳前 10 LPC-China 哺乳前+6週 10 LPC-China 哺乳前 10 對照組 2 豬隻數目 存活 死亡 病毒血症 10 0 0 10 0 0 10 0 0 10 0 0 0 2 2 24 1241346 緒之dft齡各免疫接種—次與六週齡免疫接種一次小 於試驗豬隻均_或重之ap病灶,其體溫變化 =足=,且豬隻對職強毒之抵抗力大為降低’無法阻止強毒之 曰瘦,雖Μ緒隻仍有病毒A症,但試驗豬隻皆可耐過。又,哺乳前 力^週齡各免疫接種-次與哺倾免疫接種—次之小豬,在攻毒前經 連續二天之Baytnl注射,以適當預防Ap,故在攻毒後皆未受到Ap感 染,所有試_隻體溫皆維持正“全部耐過,絲出現病毒血症及 排毒現象。她於經免麟種赌疫苗之豬t,對触之豬隻皆發高 燒且有病毒血症,並_發病壯i此,在實際田間試驗巾,Lpc_Ts 組織培養鱗疫苗顯科#相#於Lpc_china兔化舰疫苗之對於緒 隻的免疫保護效力。 實例7 : LPC-TS组織培養活毒病毒、LPC-China兔化豬瘟病毒及豬瘟野外病 毒之區分 依照實例4中豬盘病毒核酸之檢測方法,對本發明之LpC-T;s、包 括本土型及外來型之豬瘟野外毒(HCV)、LPC-China、LPC-CN及 LPC-PRK進行反轉錄聚合酶鏈反應,但其中用於增幅豬瘟病毒之特異 性引子係使用源自本發明LPC-TS株病毒之引子CP-3F及CP-6,其具 有如下序列: CP-3F : 5,-ACCCTRTTGTARATAACACTA-3,, CP-6: 5’-AAAGTGCTGTTAAAATGAGTG-3,。 病毒核酸的3’端非轉譯區12,140 bp核酸之RT-PCR電泳圖譜顯示 (如圖4所示),豬瘟野外毒及不同來源的兔化豬瘟疫苗病毒(LPC)可由 RT-PCR產物之長度差異性而明顯區分。因此,本發明之特異性引子 CP-3F及CP-6可有效區別豬瘟野外毒與兔化豬瘟(LPC-China)及組織培 25 1241346 養活毒(LPC-TS)疫苗病毒。 【圖式簡單說明】 圖1係為用於檢測PCVi存在之LPC_TS組織疫苗之PCR電泳圖譜。 圖2係為攻毒後第0至17日緒隻的平均體溫之曲線圖。 圖3係為經不同免疫計畫接種LPC-China或LPC-TS豬瘟疫苗之豬 隻在攻:秦後之平均直腸溫度之曲線圖。 圖4係為豬瘟野外毒(HCV)及不同來源兔化豬瘟疫苗毒(LPC)之3’ 端非轉譯區12,140 bp核酸之RT-PCR電泳圖譜。Results LPC-TS + 6 weeks before lactation 10 LPC-TS before lactation 10 LPC-China before lactation + 6 weeks 10 LPC-China before lactation 10 Control group 2 Number of pigs survived and died of viremia 10 0 0 10 0 0 10 0 0 10 0 0 0 2 2 24 1241346 Immunizations at dft age in sue—once and once in six-week-old vaccination—less than the average ap lesions in test pigs and their body temperature changes, foot temperature change = foot = And the pigs 'resistance to the venom is greatly reduced.' It is impossible to prevent the venom from losing weight. Although the virus still only has virus A disease, the test pigs can tolerate it. In addition, pre-lactation ^ week-old immunization-times and feeding-vaccination-second piglets were injected with Baytnl for two consecutive days before challenge to properly prevent Ap, so they were not infected with Ap after challenge. All tests have maintained a positive body temperature. "All of them have been resistant, and viremia and detoxification have occurred in the silk. She has been infected with vaccines in pigs, and all pigs that have been exposed to it have a high fever and have viremia. In this case, in actual field test towels, the Lpc_Ts Tissue Culture Squamous Vaccine Symptom # 相 # in Lpc_china Rabbit Chemical Vaccine has an immunoprotective effect on the animals. Example 7: LPC-TS tissue culture live virus, Differentiation of LPC-China Rabbit Swine Fever Virus and Swine Fever Field Virus According to the method for detecting swine disk virus nucleic acid in Example 4, the LpC-T; s of the present invention, including native and foreign swine fever field virus (HCV) , LPC-China, LPC-CN and LPC-PRK perform reverse transcription polymerase chain reaction, but the specific primers used to amplify classical swine fever virus use primers CP-3F and CP derived from the virus of the LPC-TS strain of the present invention -6, which has the following sequence: CP-3F: 5, -ACCCTRTTGTARATAACACTA-3 ,, CP-6: 5'-AAAGTGCTGTTAAAATGAGTG-3 ,. RT-PCR electrophoresis pattern of 12,140 bp nucleic acid in the 3 'untranslated region of viral nucleic acid (shown in Figure 4), swine fever field virus and rabbits of different origin The plague vaccine virus (LPC) can be clearly distinguished by the difference in the length of the RT-PCR products. Therefore, the specific primers CP-3F and CP-6 of the present invention can effectively distinguish swine fever field virus from rabbit swine fever (LPC-China). ) And tissue culture 25 1241346 Feeding virus (LPC-TS) vaccine virus. [Schematic description] Figure 1 is a PCR electrophoresis map of the LPC_TS tissue vaccine used to detect the presence of PCVi. Figure 2 is 0 to 0 after challenge The average body temperature curve of the 17th day of the year. Figure 3 is a graph of the average rectal temperature of pigs vaccinated with LPC-China or LPC-TS swine fever vaccine under different immunization plans: after Qin Dynasty. Figure 4 RT-PCR electrophoresis map of 12,140 bp nucleic acid in the 3 'untranslated region of classical swine fever field virus (HCV) and rabbit-derived swine fever vaccine virus (LPC) from different sources.
2626
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW92134947A TWI241346B (en) | 2003-12-11 | 2003-12-11 | Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same |
MYPI20045116A MY146370A (en) | 2003-12-11 | 2004-12-10 | Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW92134947A TWI241346B (en) | 2003-12-11 | 2003-12-11 | Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200519210A TW200519210A (en) | 2005-06-16 |
TWI241346B true TWI241346B (en) | 2005-10-11 |
Family
ID=37013926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW92134947A TWI241346B (en) | 2003-12-11 | 2003-12-11 | Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same |
Country Status (2)
Country | Link |
---|---|
MY (1) | MY146370A (en) |
TW (1) | TWI241346B (en) |
-
2003
- 2003-12-11 TW TW92134947A patent/TWI241346B/en not_active IP Right Cessation
-
2004
- 2004-12-10 MY MYPI20045116A patent/MY146370A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200519210A (en) | 2005-06-16 |
MY146370A (en) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107815441B (en) | Type II pseudorabies virus attenuated strain and preparation method and application thereof | |
TWI508974B (en) | Porcine circovirus type 2, immunogenic composition containing the same, test kit, and application thereof | |
Wright | Serological and genetic characterisation of putative new serotypes of bluetongue virus and epizootic haemorrhagic disease virus isolated from an alpaca | |
CN108064165A (en) | Porcine epidemic diarrhea virus strain and the immunogenic composition being generated by it | |
RU2710041C2 (en) | Pestiviruses | |
CN107513524A (en) | One plant of pig Sai Neijia paddy virus stain and its application | |
CN101914503B (en) | Canine distemper attenuated vaccine strain and application thereof | |
CN102221618B (en) | Method for establishing hog cholera lapinized virus labeled vaccine strain and preparing vaccine | |
CN111876391A (en) | Feline panleukopenia virus FPV BJ05 strain and application thereof | |
CN110872578A (en) | Variant infectious bursal disease virus, subunit vaccine, preparation method and application thereof | |
CN114561366B (en) | Goat kuraria virus isolate and application thereof | |
CN105112349B (en) | A kind of brucella melitensis molecular marker vaccine strain and its application | |
AU2016315796B2 (en) | Pestivirus vaccines for congenital tremors | |
CN106854647B (en) | Duck viral hepatitis bivalent yolk antibody and preparation method and application thereof | |
WO2020099293A1 (en) | Novel porcine rotavirus | |
CN102167735A (en) | Recombinant antigen protein of S.japonicum SjTollip and preparation method and application thereof | |
CN111729091B (en) | Method for checking efficacy of porcine Seika virus inactivated vaccine by using rabbit | |
CN105802921B (en) | Recombinant pseudorabies virus variant strain for expressing classical swine fever virus E2protein and construction method and application thereof | |
CN109745555B (en) | Mycoplasma hyopneumoniae and haemophilus parasuis combined inactivated vaccine and application thereof | |
CN105200015B (en) | A kind of porcine pseudorabies strain | |
CN111686246B (en) | Antigen-antibody complex vaccine for porcine epidemic diarrhea virus and preparation method thereof | |
TWI241346B (en) | Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same | |
CN101496899B (en) | Prevention, treatment and detection of progressive atrophic rhinitis of pig | |
CN111097044A (en) | Canine leptospira, icterohepaemic leptospira and canine coronavirus triple inactivated vaccine | |
CN108707589A (en) | A kind of bovine viral diarrhea virus SMU-Z6/1a/SC/2016 separation strains and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |